Table 1.
Patient demographics and tumor characteristics
| Parameters | No. of patients | Percent (%) |
|---|---|---|
| Sex | ||
| Male | 24 | 44.4 |
| Female | 30 | 55.6 |
| Age at onset | ||
| Mean | 52.5 | |
| Median | 54.0 | |
| Range | 24–76 | |
| Age at the beginning of STZ administration | ||
| Mean | 56.0 | |
| Median | 56.0 | |
| Range | 31–77 | |
| Performance status | ||
| 0 | 34 | 63.0 |
| 1 | 17 | 31.5 |
| 2 | 3 | 5.5 |
| 3–4 | 0 | 0.0 |
| Primary site | ||
| Pancreaticoduodenal NET | (46) | (85.2) |
| Pancreas head | 12 | 26.1 |
| Pancreas body | 10 | 21.7 |
| Pancreas tail | 19 | 41.3 |
| Head, body and tail | 1 | 2.2 |
| Duodenal | 4 | 8.7 |
| Gastrointestinal NET | (8) | (14.8) |
| Stomach | 2 | 25.0 |
| Small Intestine | 1 | 12.5 |
| Rectum | 4 | 50.0 |
| Others | 1 | 12.5 |
| Pathological diagnosis (WHO 2000) | ||
| Well-differentiated endocrine tumor | 0 | 0.0 |
| Well-differentiated endocrine carcinoma | 52 | 96.4 |
| Poorly-differentiated endocrine carcinoma/small cell carcinoma | 1 | 1.8 |
| Others | 1 | 1.8 |
| Functioning NET/non-functioning NET | ||
| Functioning | (18) | (33.3) |
| Gastrinoma | 9 | 16.7 |
| Insulinoma | 7 | 13.0 |
| Glucagonoma | 4 | 7.4 |
| Somatostatinoma | 1 | 1.9 |
| Serotonin, tachykinins producing tumor | 1 | 1.9 |
| Non-functioning | (36) | (66.7) |
| Metastatic site(s) | ||
| Liver | 53 | 98.1 |
| Lymph nodes | 26 | 48.1 |
| Peritoneum | 3 | 5.6 |
| Lung | 2 | 3.7 |
| Others | 10 | 18.5 |